1. Scrip
  2. >>Business
  3. >>Deals

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Sanofi
• Source: Shutterstock

Sanofi’s immunology pipeline has suffered a couple of high-profile setbacks recently so the proposed acquisition of Blueprint Medicines Corp and Ayvakit, its already-approved therapy for advanced systemic mastocytosis (SM), should calm investors who may have been concerned by the riskier early-stage deals the French major has been pursuing.

Key Takeaways
  • Sanofi's proposed $9.1bn acquisition of Blueprint looks like a sound bit of business given that Ayvakit is well on the road to blockbuster status.

The eye-catching deal, announced on 2 June, will see Sanofi pay $129.00 per share in cash, representing an equity value...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D

 
• By Joseph Haas and Sushmita Panda

Also deals involving Lyell/Innovative Cellular, Lilly/Ailux, Dynavax/Vaxart, AVEO/HiberCell, Incyte/Prelude, AmacaThera/Pacira, Roche/Manifold and Chromatin/Purespring.

Jefferies Conference 2025: Five Themes To Follow

 
• By Andrew McConaghie

The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

A Week Is A Long Time In Biotech, Just Ask Galecto

 
• By Kevin Grogan

A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.

More from Advanced Therapies

BioMarin Looks To Offload Roctavian As Gene Therapy’s Sales Drop

 
• By Alaric DeArment

The company said in its third quarter earnings that it would focus on areas that better foster growth for the company as the hemophilia A treatment only brought in $3m in Q3.

Intellia Hits Pause On Phase III Nex-z Studies After Second Liver Enzyme Event

 
• By Alaric DeArment

The company reported that a patient went to the emergency room after experiencing grade 4 transaminase elevations, which unlike a similar event in May caused symptoms.

Novartis Still Has Significant M&A Firepower After Avidity Acquisition

 
• By Kevin Grogan

The Basel-based company has faith in its existing rare disease commercial platform to successfully market the newly-acquired assets.